FDA grants Fast Track designation to novel immunotherapy targeting solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FDA granted Fast Track designation to CT-0508, a human epidermal growth factor receptor 2 targeted chimeric antigen receptor macrophage for the treatment of patients with solid tumors.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login